Kartagener Syndrome

Definition

1. Situs inversus (complete mirror-image reversal of visceral organs)
2. Chronic sinusitis (and/or nasal polyposis)
3. Bronchiectasis

• K.J. Lee's Essential Otolaryngology
• Scott-Brown's Otorhinolaryngology Head & Neck Surgery, Vol. 1

Genetics & Epidemiology

• Inheritance: Autosomal recessive
• Prevalence: ~1 in 20,000 births
• Genetics: More than 45 genes are now known to cause PCD. Mutations affect genes encoding dynein arm proteins (e.g., DNAI1, DNAI2, DNAH5, DNAH11) and other structural components of cilia/flagella.
• Men and women are equally affected in terms of respiratory disease.
• Histology: A Text and Atlas, 9th ed.
• The Harriet Lane Handbook, 23rd ed.

Pathophysiology

• Dynein arms are absent (both outer and inner) on the microtubule A-tubules
• Basal feet are misoriented, pointing in random directions rather than uniformly (seen on EM)
• The result is absent or severely impaired ciliary motility

• Histology: A Text and Atlas, 9th ed.
• Junqueira's Basic Histology, 17th ed.

Electron Micrograph - Absent Dynein Arms

Clinical Features

• Recurrent lower respiratory tract infections since childhood
• Chronic productive cough
• Bilateral bronchiectasis - basal/lower-middle lobe predominance, usually cylindrical type
• Chronic rhinosinusitis
• Nasal polyposis (27% of Kartagener patients)
• Recurrent otitis media
• Asthma-like symptoms

• Complete visceral transposition (dextrocardia, liver on the left, etc.)
• Important clinical point: ECG leads and auscultation findings are mirror-image
• Seen on CXR as dextrocardia (heart apex pointing right)

• Males: nearly complete or total infertility due to immotile but metabolically active sperm. Sperm motility <10% is a hallmark. Azoospermia is uncommon; the sperm are present but immotile.
• Females: potentially fertile, but increased risk of ectopic pregnancy due to impaired cilia transport in the Fallopian tubes

• Hydrocephalus or transient ventricular dilatation from impaired ependymal cilia
• Campbell-Walsh-Wein Urology
• Grainger & Allison's Diagnostic Radiology
• Scott-Brown's Otorhinolaryngology

Chest X-Ray Findings

• CXR/CT: dextrocardia, situs inversus, bilateral bronchiectasis (lower > upper lobe), diffuse bronchiolitis
• CT sinuses: mucosal thickening, opacification of sinuses

Diagnosis

1. Clinical suspicion: classic triad + childhood onset respiratory symptoms
2. Nasal NO (nitric oxide): very low nasal NO is a sensitive screening test for PCD
3. Electron microscopy (EM): gold standard - shows absent dynein arms and/or misoriented basal feet
4. High-speed video microscopy: demonstrates abnormal or absent ciliary beat
5. Genetic testing: >45 causative genes; broad gene panel testing recommended
6. Semen analysis: <10% motility; EM of sperm tail may show structural defects
7. Evaluation of other organ systems: abdominal US, echocardiogram, brain MRI

• The Harriet Lane Handbook, 23rd ed.
• Histology: A Text and Atlas, 9th ed.

Differential Diagnosis

• Cystic fibrosis - also causes bronchiectasis, sinusitis, and infertility, but due to CFTR mutation (chloride channel), not ciliary defect
• Common variable immunodeficiency - recurrent sinus and pulmonary infections, but no situs inversus or GI involvement
• Young's syndrome - bronchiectasis + sinusitis + obstructive azoospermia, but normal ciliary ultrastructure (radial spoke/dynein malformation)
• The Washington Manual of Medical Therapeutics
• Scott-Brown's Otorhinolaryngology

Management

• Airway clearance: chest physiotherapy, postural drainage, oscillating positive expiratory pressure devices
• Antibiotics: prompt and aggressive treatment of respiratory infections; long-term prophylactic macrolides (azithromycin) are used in some centers
• Bronchodilators/inhaled corticosteroids for airway inflammation
• Sinus surgery (FESS): for refractory chronic sinusitis / nasal polyps
• Fertility: males with Kartagener syndrome may father children using intracytoplasmic sperm injection (ICSI), as the sperm are viable despite being immotile
• Genetic counseling: autosomal recessive - 25% recurrence risk for siblings
• Regular surveillance: spirometry, sputum cultures, CT chest

Key Points Summary

Fabry Disease - Management

Background (Brief)

Angiokeratomas clustered over the lower trunk - Bradley & Daroff's Neurology in Clinical Practice

Management Overview

1. Disease-specific therapy - enzyme replacement therapy (ERT) or pharmacological chaperone therapy
2. Organ-specific / symptomatic supportive therapy

1. Disease-Specific Therapies

A. Enzyme Replacement Therapy (ERT)

• All adult males with confirmed Fabry disease
• Symptomatic boys
• Symptomatic heterozygous females
• Initiated before irreversible end-organ damage for maximum benefit

• Clears microvascular endothelial Gb3 deposits from target organs
• Slows progression of renal, cardiac, and cerebrovascular complications
• Improves neuropathic pain, quality of life, GI symptoms, hypohidrosis, and autonomic function
• Better outcomes when started early - higher baseline proteinuria, worse initial GFR, and delayed therapy are strong predictors of renal progression despite ERT
• Mean annual GFR decline on agalsidase alfa: -2.2 mL/min/1.73m² in men, -0.7 in women (FOS registry data)

• Infusion-related reactions: fever, rigors, chills, flushing, chest discomfort, rash, pruritus, nasal congestion (>50% during first months)
• IgG or IgE antibodies may develop - can inhibit ERT efficacy
• Management of reactions: reduce infusion rate, antihistamines, paracetamol/acetaminophen, corticosteroids; pre-medicate if needed
• ERT can be administered during dialysis sessions
• National Kidney Foundation Primer on Kidney Diseases, 8th ed.
• Bradley & Daroff's Neurology in Clinical Practice

B. Pharmacological Chaperone Therapy - Migalastat

• Phase III ATTRACT trial (18-month, randomized): migalastat was non-inferior to ERT in eGFR decline and superior in reducing LV mass index
• FAMOUS observational study confirms real-world efficacy
• Reduces plasma lyso-Gb3 (treatment monitoring biomarker)

• National Kidney Foundation Primer on Kidney Diseases, 8th ed.
• Goldman-Cecil Medicine

C. Emerging / Investigational Therapies

• National Kidney Foundation Primer on Kidney Diseases, 8th ed.

2. Organ-Specific Supportive Management

Pain (Acroparesthesias)

• Bradley & Daroff's Neurology in Clinical Practice
• National Kidney Foundation Primer on Kidney Diseases, 8th ed.

Kidney Disease

• Comprehensive Clinical Nephrology, 7th ed.
• National Kidney Foundation Primer on Kidney Diseases, 8th ed.

Cardiac Management

• Braunwald's Heart Disease, 11th ed.
• Eur Heart J 2024 (PMID 38486361)

Cerebrovascular Disease

Other Supportive Treatments

• National Kidney Foundation Primer on Kidney Diseases, 8th ed.
• Scott-Brown's / Bradley & Daroff's

3. Monitoring During Treatment

• Plasma lyso-Gb3: primary biomarker for treatment response and disease activity
• Urine Gb3: elevated early, decreases with ERT
• eGFR + urine protein: annual minimum
• Echocardiogram + ECG: annual (LV mass, wall thickness, valves, conduction)
• Brain MRI: every 2-3 years, or as indicated
• Anti-α-Gal A antibodies: check if poor response to ERT; antibody-mediated inhibition of ERT is a recognized mechanism of treatment failure

4. Diagnosis Essentials (Before Starting Treatment)

5. Treatment Decision Algorithm (Summary)

Confirmed Fabry disease
         |
         ├── Amenable GLA mutation?
         │         YES → Migalastat 123 mg oral every other day
         │         NO  → ERT (agalsidase beta 1 mg/kg IV q2w [US]
         │                or agalsidase alfa 0.2 mg/kg IV q2w [EU])
         │
         ├── Kidney failure → Transplant preferred over dialysis
         │
         ├── Pain → Anticonvulsants (carbamazepine/pregabalin)
         │
         ├── Cardiac → ERT + standard HF/arrhythmia management
         │
         └── Stroke prevention → Antiplatelets ± anticoagulation